Cangene Corporation’s Anti-Hepatitis B Product Granted Orphan-Drug Exclusive Approval by the U.S. FDA

TORONTO and WINNIPEG, March 26 /CNW/ - Cangene Corporation today announces that its HepaGam B(TM) (Hepatitis B Immune Globulin Intravenous (Human)), has received orphan-drug exclusive approval from the United States Food and Drug Administration (“FDA”) for the prevention of hepatitis B recurrence following liver transplantation in hepatitis B surface antigen (“HbsAG”)-positive liver transplant patients. This approval gives HepaGam B seven years of market exclusivity and could facilitate the recovery of certain regulatory filing fees.